Q2 EPS Forecast for Bio-Rad Laboratories Reduced by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities research analysts at Zacks Research reduced their Q2 2025 earnings estimates for shares of Bio-Rad Laboratories in a research report issued on Thursday, July 10th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $1.93 per share for the quarter, down from their previous forecast of $2.03. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $2.57 EPS, FY2025 earnings at $9.23 EPS, Q1 2026 earnings at $2.79 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.78 EPS, FY2026 earnings at $10.52 EPS and Q1 2027 earnings at $2.45 EPS.

BIO has been the subject of several other research reports. Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Royal Bank Of Canada reduced their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Citigroup reduced their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating for the company in a research note on Monday, June 9th. Finally, UBS Group reduced their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $324.25.

Bio-Rad Laboratories Stock Down 1.0%

BIO stock opened at $257.34 on Friday. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $387.99. The company has a fifty day simple moving average of $237.15 and a 200 day simple moving average of $269.58. The firm has a market cap of $7.00 billion, a PE ratio of -3.38 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business had revenue of $585.40 million for the quarter, compared to analysts’ expectations of $573.01 million. During the same period in the previous year, the company posted $2.30 EPS. Bio-Rad Laboratories’s revenue was down 4.2% on a year-over-year basis.

Institutional Trading of Bio-Rad Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. New York State Teachers Retirement System grew its stake in Bio-Rad Laboratories by 1.2% during the first quarter. New York State Teachers Retirement System now owns 17,500 shares of the medical research company’s stock worth $4,262,000 after buying an additional 200 shares during the last quarter. Asset Management One Co. Ltd. grew its stake in Bio-Rad Laboratories by 4.6% during the first quarter. Asset Management One Co. Ltd. now owns 7,182 shares of the medical research company’s stock worth $1,749,000 after buying an additional 315 shares during the last quarter. Blue Trust Inc. grew its stake in Bio-Rad Laboratories by 35.2% during the first quarter. Blue Trust Inc. now owns 1,438 shares of the medical research company’s stock worth $350,000 after buying an additional 374 shares during the last quarter. LPL Financial LLC grew its stake in Bio-Rad Laboratories by 34.3% during the fourth quarter. LPL Financial LLC now owns 5,195 shares of the medical research company’s stock worth $1,707,000 after buying an additional 1,326 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC bought a new stake in Bio-Rad Laboratories during the fourth quarter worth about $245,000. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.